Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety
Sleep Medicine review authors
Published in Sleep Medicine
Methodology
Systematic review of trials and observational studies of pharmacological treatments for REM sleep behaviour disorder in synucleinopathies, assessing reduction in dream-enactment behaviour and adverse events.
Key Findings
Across included studies, clonazepam and melatonin were the most used agents for REM sleep behaviour disorder, with melatonin favoured for tolerability in older patients, but effect estimates were inconsistent and drawn mostly from small or uncontrolled studies.
Conclusions
Clonazepam and melatonin remain the principal treatments in practice, but evidence was limited and inconsistent.
Limitations
Few randomized controlled trials, small samples, heterogeneous outcome measures often based on subjective report rather than polysomnography, and no quantitative pooling.
Supplements Studied
Clonazepam and melatonin remain the principal treatments in practice, but evidence was limited and inconsistent.
Outcomes Measured
Across included studies, clonazepam and melatonin were the most used agents for REM sleep behaviour disorder, with melatonin favoured for tolerability in older patients, but effect estimates were inconsistent and drawn mostly from small or uncontrolled studies.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.